The global Smallpox Treatment Market is estimated to be valued at US$ 68.7 Million in 2023 and is expected to exhibit a CAGR of 1.8% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Smallpox is a contagious and potentially deadly disease caused by the variola virus and poses a serious global health threat. Smallpox vaccines help prevent the spread of the virus by triggering an immune response. These vaccines provide long term immunity against smallpox and help control outbreaks.

Market key trends:

One of the key trends in the smallpox treatment market is the development of freeze-dried vaccines with longer shelf life. Traditionally, smallpox vaccines need to be stored frozen which limits their usability. However, new technologies are allowing vaccine manufacturers to develop freeze-dried formulations with 5 years of stability at room temperature. These thermostable vaccines can overcome issues of cold chain management and allow for stockpiling of vaccines. They also improve access to vaccines in remote areas without refrigeration facilities. Furthermore, efforts to develop new smallpox vaccines are also growing in light of bioterrorism threats. Researchers are working on developing safer and more effective third generation vaccines.

Segment Analysis

The global smallpox treatment market is dominated by dryvax vaccines segment. Dryvax vaccine is an FDA-approved live replicating vaccinia virus vaccine for preventing smallpox. It induces both cellular and humoral immune responses and produces immunological memory that may persist for over 60 years. Majority of the population is vaccinated with the Dryvax vaccine which is mainly driving the growth of this segment.

Key Takeaways

The Global Smallpox Treatment Market Size is expected to grow at CAGR of 1.8% over the forecast period, due to growing incidence of smallpox infection and strengthening government support for the production of smallpox vaccines and drugs.

Regional analysis

North America dominated the smallpox treatment market in 2023 and is expected to continue its dominance over the forecast period. Factors such as strong biopharmaceutical industry, increasing R&D expenditures by governments, and high healthcare spending are expected to drive the market in the region.

Key players

Key players operating in the smallpox treatment market are SIGA Technologies Inc., Bavarian Nordic A/S, Takeda Pharmaceutical Company Limited, Johnson & Johnson, Emergent BioSolutions Inc., Novartis International AG, GlaxoSmithKline plc, Sanofi Pasteur SA, Merck & Co. Inc., Pfizer Inc., Bharat Biotech International Ltd., BioCryst Pharmaceuticals Inc., Chimerix  Inc., Nanotherapeutics Inc., Bavarian Nordic A/S. SIGA Technologies Inc. has the highest share in the market due to its flagship smallpox antiviral - TPOXX.

Read more

https://www.dailyprbulletin.com/smallpox-treatment-market-size-share-growth-outlook-2023/